Telephone
1.952.818.8400
Address
400 Gateway Boulevard Burnsville, MN 55337
Description
Imricor Medical Systems, Inc. is a medical device company, which engages in the design, manufacture, and distribution of magnetic resonance imaging (MRI) compatible products for cardiac catheter ablation procedures. The firm offers the Advantage-MR EP Recorder/Stimulator system, an electrophysiology amplifier and recording system with integrated cardiac stimulator, Vision-MR Ablation Catheter, which is used as an indication for treating type I atrial flutter, and Vision-MR Dispersive Electrode, an ablation dispersive electrode that is used to minimize eddy currents induced on the conductive pads during MR scanning. It also performs contract research, as well as licenses its intellectual property for use in implantable devices. The company was founded by Steven Wedan in 2006 and is headquartered in Burnsville, MN.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.4 - 0.81
Trade Value (12mth)
AU$14,485.00
1 week
-6.45%
1 month
16%
YTD
8.89%
1 year
36.11%
All time high
2.85
EPS 3 yr Growth
-14.700%
EBITDA Margin
%
Operating Cashflow
-$13m
Free Cash Flow Return
N/A
ROIC
N/A
Interest Coverage
N/A
Quick Ratio
N/A
Shares on Issue (Fully Dilluted)
156m
HALO Sector
Healthcare
Next Company Report Date
19-Feb-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
19 July 24 |
Imricor Successfully Raises A$35 Million via Placement
×
Imricor Successfully Raises A$35 Million via Placement |
19 July 24 |
Equity Raising Presentation
×
Equity Raising Presentation |
19 July 24 |
Proposed issue of securities - IMR
×
Proposed issue of securities - IMR |
17 July 24 |
Trading Halt
×
Trading Halt |
16 July 24 |
Release from Voluntary Escrow
×
Release from Voluntary Escrow |
01 July 24 |
Imricor Completes Capital Equipment Installation at CHUV
×
Imricor Completes Capital Equipment Installation at CHUV |
28 June 24 |
Successful Completion of Second Case by Dubrava
×
Successful Completion of Second Case by Dubrava |
26 June 24 |
Imricor Wins New Customer in Hungary
×
Imricor Wins New Customer in Hungary |
21 June 24 |
Imricor Commences VISABL-AFL Trial for US FDA Approval
×
Imricor Commences VISABL-AFL Trial for US FDA Approval |
20 June 24 |
Commencement of Procedures at Dubrava University Hospital
×
Commencement of Procedures at Dubrava University Hospital |
13 June 24 |
Notification of cessation of securities - IMR
×
Notification of cessation of securities - IMR |
12 June 24 |
Notification regarding unquoted securities - IMR
×
Notification regarding unquoted securities - IMR |
12 June 24 |
Appendix 3Y - SW
×
Appendix 3Y - SW |
27 May 24 |
Appendix 3Y - PM
×
Appendix 3Y - PM |
27 May 24 |
Appendix 3Y - MT
×
Appendix 3Y - MT |
27 May 24 |
Appendix 3Y - AM
×
Appendix 3Y - AM |
24 May 24 |
Appendix 3Y - Purchase of Shares by Chair
×
Appendix 3Y - Purchase of Shares by Chair |
22 May 24 |
Application for quotation of securities - IMR
×
Application for quotation of securities - IMR |
15 May 24 |
Annual Meeting of Stockholders Chair's Address
×
Annual Meeting of Stockholders Chair's Address |
15 May 24 |
Annual Stockholder Meeting Presentation Slides
×
Annual Stockholder Meeting Presentation Slides |
15 May 24 |
Results of Meeting
×
Results of Meeting |
09 May 24 |
Swissmedic Approval for VISABL-AFL Clinical Trial at CHUV
×
Swissmedic Approval for VISABL-AFL Clinical Trial at CHUV |
08 May 24 |
Appendix 3Y - PM
×
Appendix 3Y - PM |
02 May 24 |
Release from Voluntary Escrow
×
Release from Voluntary Escrow |
30 April 24 |
Imricor Q1 CY24 Quarterly Activities Report and Appendix 4C
×
Imricor Q1 CY24 Quarterly Activities Report and Appendix 4C |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.